A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton pump inhibitor (PPI). An 8 week, open label, multicentre study.
- Registry ID
- EUCTR2006-000257-22
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- AstraZeneca UK Ltd
- Start date
- 2006-06-02
- Completion date
- 2007-06-11
- Last update
- 2026-08-16
Conditions
- Gastroesophageal Reflux Disease (GORD)
Summary
The primary objective of this study is to assess the change in the frequency of heartburn from baseline value at entry to the end of the study, after 8-weeks treatment with Esomeprazole 40mg compared to previous full dose treatment with a PPI given once daily.
Locations
View on source registry